Moomoo AI 已提取核心信息
Christopher Krawtschuk, the Chief Financial Officer of bluebird bio, Inc. [BLUE], has been reported to engage in a transaction involving the company's stock. The action took place on March 1, 2024. However, the announcement did not disclose the number of shares transacted, the nature of the shares, the transaction price, or the total value of the shares involved. Additionally, the number of shares held by Krawtschuk after the transaction was not provided. The lack of details in the report leaves the specifics of the transaction unclear.
Christopher Krawtschuk, the Chief Financial Officer of bluebird bio, Inc. [BLUE], has been reported to engage in a transaction involving the company's stock. The action took place on March 1, 2024. However, the announcement did not disclose the number of shares transacted, the nature of the shares, the transaction price, or the total value of the shares involved. Additionally, the number of shares held by Krawtschuk after the transaction was not provided. The lack of details in the report leaves the specifics of the transaction unclear.
据报道，蓝鸟生物公司 [BLUE] 的首席财务官克里斯托弗·克劳茨丘克参与了一项涉及该公司股票的交易。该行动于 2024 年 3 月 1 日进行。但是，该公告没有透露交易的股票数量、股票的性质、交易价格或所涉股票的总价值。此外，没有提供Krawtschuk在交易后持有的股票数量。报告中缺乏细节，使交易的细节尚不清楚。
据报道，蓝鸟生物公司 [BLUE] 的首席财务官克里斯托弗·克劳茨丘克参与了一项涉及该公司股票的交易。该行动于 2024 年 3 月 1 日进行。但是，该公告没有透露交易的股票数量、股票的性质、交易价格或所涉股票的总价值。此外，没有提供Krawtschuk在交易后持有的股票数量。报告中缺乏细节，使交易的细节尚不清楚。
有用
没用